Approved medicines Human trials in product label Hormone research
Also discussed as: Egrifta, Egrifta SV
What it is and how it works
Tesamorelin is a growth hormone-releasing factor analogue. It stimulates pituitary growth-hormone release and increases IGF-1. That pathway explains why both intended effects and endocrine safety concerns appear in the prescribing information.
Source for the mechanism context →A closer look at the cited evidence
Human trials in product label
This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.
- Study or assessment
- DailyMed — Egrifta SV mechanism and clinical studies
- Design
- The label summarizes controlled clinical trials and safety findings.
- Who or what was studied
- Adults with HIV-associated lipodystrophy; the clinical question concerns excess abdominal fat.
- What was observed
- The trials underpin a specific medical indication rather than a general body-composition claim.
- Limits of interpretation
- This is not evidence that tesamorelin is an appropriate general weight-loss or anti-aging intervention. Long-term cardiovascular safety is not established in the label.
What the evidence means
Clinical evidence and labeling address excess abdominal fat in adults with HIV-associated lipodystrophy, not general fitness goals.
Approval and regulatory context
Egrifta SV has a specific FDA-approved indication. It is not indicated for general weight-loss management.
Safety and uncertainty
Label warnings include elevated IGF-1, glucose intolerance, and fluid retention. Contraindications include active malignancy and pregnancy. This is not a complete risk list.
What remains uncertain
Whether a change in abdominal fat translates into every hoped-for long-term outcome is a separate question. Results in this patient population should not be transferred to healthy adults seeking a different goal.
These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.
Sources behind this overview
Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.